Navigation Links
PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL
Date:5/30/2008

n, affecting less than 200,000 individuals in the United States.(1)

Eltrombopag is an investigational, once-daily oral treatment developed to induce the production of cells in the bone marrow to increase platelets, which are critical in minimizing the incidence of bleeding in chronic ITP.

Eltrombopag, a novel oral thrombopoeitin (TPO) receptor agonist, if approved, would be the first oral short-term treatment of previously treated patients with chronic ITP to increase platelet counts and reduce or prevent bleeding.

In the pivotal studies, the most common adverse events observed in patients taking eltrombopag were headache, nasopharyngitis, and nausea.

About the data

The NDA submission is supported by the largest database of clinical trial information on investigational therapies for chronic ITP patients. Two pivotal trials (one Phase III trial and one Phase II trial), were submitted to support the filing.

About ITP

Chronic ITP is a disorder marked by increased platelet destruction and/or inadequate platelet production in the blood, which causes an increased risk of bruising and bleeding.(2,3) There are estimated to be approximately 60,000 individuals diagnosed with chronic ITP in the U.S.(4) People with chronic ITP often bleed from small blood vessels causing bruises, nosebleeds or even fatal gastrointestinal or intra cerebral bleeds, although these are rare.(3)

About Eltrombopag

Eltrombopag is an oral, non-peptide thrombopoietin receptor agonist that has been shown in pre-clinical research and clinical trials to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals (Nasdaq:

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder
2. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
3. DaVita Receives Civil Complaint
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
5. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
6. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
7. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
8. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
9. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
10. Prime Therapeutics Receives TIPPS Certification
11. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... African Americans know and think little about lung cancer, African ... the disease that could interfere with prevention and treatment. Published ... the American Cancer Society, the report indicates that public health ... Lung cancer is the leading cause of cancer deaths ...
... , ... ... ... ...
... born as a result of assisted reproductive technologies since the ... While the majority of these children are healthy and normal, ... kinds of birth defects and being low birth weight, which ... in life. Carmen Sapienza, a geneticist at Temple University ...
... ... ... ... ...
... suggest , SATURDAY, Feb. 20 (HealthDay News) -- The ... for heart attack and heart failure and should be ... , The New York Times on Saturday ... Administration that find that if people now taking (rosiglitazone) ...
... ... company has already positioned itself as a powerful player in the online market of pure ... that can be purchased via creditcards! , ... (PRWEB) February 20, 2010 -- The war is raging in the online world ...
Cached Medicine News:Health News:Survey finds significant racial differences in lung cancer beliefs 2Health News:Live with Regis and Kelly Reveal A REVOLUTIONARY Pain Relief Method 2Health News:Live with Regis and Kelly Reveal A REVOLUTIONARY Pain Relief Method 3Health News:Tony Blair Visits Pioneering Interfaith Malaria Initiative in Nigeria 2Health News:Tony Blair Visits Pioneering Interfaith Malaria Initiative in Nigeria 3Health News:Tony Blair Visits Pioneering Interfaith Malaria Initiative in Nigeria 4Health News:Tony Blair Visits Pioneering Interfaith Malaria Initiative in Nigeria 5Health News:Tony Blair Visits Pioneering Interfaith Malaria Initiative in Nigeria 6Health News:Tony Blair Visits Pioneering Interfaith Malaria Initiative in Nigeria 7Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 2Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 3Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 4Health News:Sun Spark Purity Moves Aggressively into the Market of Pure Lidocaine Powder and Caffeine Powder 2Health News:Sun Spark Purity Moves Aggressively into the Market of Pure Lidocaine Powder and Caffeine Powder 3
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ...
(Date:1/14/2014)... 2014 Animal Emergency Critical Care, a LifeCentre partner practice, located ... is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is a well-seasoned ... Cole Taylor , are avid scuba divers. "As altitude skiers ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Therapies, Inc. (ITI),today announced it has initiated a ... its drug candidate ITI-722. ITI-722 acts predominantly,as a ... new,approach to the treatment of SMI. Because of ... activities, ITI believes, ITI-722 can be,used not only ...
... GeoVax Labs, Inc. (OTC,Bulletin Board: GOVX), an ... it has retained Financial,Relations Board (FRB), as its ... promising HIV-1/AIDS vaccine human trial results need to ... catastrophic AIDS,pandemic," stated Kathy Waller, co-president of FRB., ...
Cached Medicine Technology:Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 2Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 3Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 4GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel 2GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel 3GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel 4
Inquire...
... A fast, reliable and accurate immunoassay ... and plasma. , ,The fully automated Elecsys ... failure in symptomatic patients. NT-proBNP levels also ... allow the assessment of prognosis. In addition, ...
... there is a more efficient way ... fully portable battery operated patient warming ... surgical teams with a compact and ... the entire surgical process. Its unique ...
... system consists of our compact and ... blankets for use with patients of ... Blankets are available for intra and ... sizes and a sterile cardiac blanket ...
Medicine Products: